American Society of Clinical Oncology Genitourinary Cancers Symposium
ASCO-GU 2022
This program was supported by Bayer Inc.
Prostate cancer conference highlights
AUDIO & VIDEO CAPSULES
Moderated by Dr. Steven Yip
Abstract Summaries
Dr Sebastien Hotte (English)
Watch video capsule
Abstract Summaries
Dr. Sebastien Hotte (French)
Abstract 13 – Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
Watch video capsule
Abstract Summaries
Dr. Lucia Nappi
Abstract 12 – Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations
Watch video capsule
Abstract Summaries
Dr. Laurence Klotz
Abstract 11 – PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Watch video capsule
Abstract Summaries
Dr. Tamim Niazi
Poster 256 – Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS
Watch video capsule
Abstract Summaries
Dr. Ramy Saleh
Abstract 10 – PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)
Watch video capsule
The opinions expressed in these capsules are those of the physicians.
The contents of this site may contain information regarding indications and/or instructions which differ from the approved use of products available in Canada. For complete information, please refer to the respective conference sessions and product monographs available through the manufacturer’s website. The safety and efficacy of some of the products described herein are still under investigation and have not received market authorization from Health Canada.
This website is intended for Canadian healthcare professionals.
MA-M_DAR-CA-0227